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Original Article
family. It influences cell matrix interactions, cell 
functions, tissue remodeling, wound repair, and type I 
collagen fibrillogenesis in periodontal ligament.[2,3] It is 
induced by transforming growth factor‑beta (TGF‑β) 
and modulates matrix‑cell interactions relevant to 
connective tissue repair.[4‑6]
Periostin knock‑out mice experiments have shown 
defective remodeling in periodontal ligament 
INTRODUCTION
Periodontitis is an inflammatory disease caused by 
specific microorganisms resulting in progressive 
destruction of the supporting tissues of the teeth. 
The host response causes the release of inflammatory 
mediators and cytokines leading to periodontal 
breakdown.[1]
Periostin a matricellular protein earlier termed 
osteoblast specific factor – 2 belongs to the Fasciclin – I 
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ABSTRACT
Objective: Periostin is a matricellular protein highly expressed in periosteum, periodontal ligament and is essential for tissue 
integrity and maturation. It plays a role in collagen fibrillogenesis and is downregulated in periodontal disease. Biostimulation 
utilizing low‑level laser therapy (LLLT) influences periodontal ligament fibroblast proliferation. This study was conducted with 
the objective of estimating periostin levels in chronic periodontitis (CP) patients following LLLT as an adjunct to root surface 
debridement (RSD). Materials and Methods: Thirty periodontally healthy participants (Group I) and sixty CP participants 
were recruited. Based on the therapeutic intervention, CP patients were allocated to either RSD (Group II) or to RSD with 
LLLT (Group III) group. Clinical parameters and gingival crevicular fluid (GCF) periostin levels were assessed at the baseline 
and at the 3rd month. Results: Periostin levels were significantly lower in CP patients when compared to healthy individuals at the 
baseline (P < 0.01). Following nonsurgical periodontal treatment (NSPT), periostin levels significantly increased in both Group II 
and III, when compared to baseline values (P < 0.001). Comparison of mean periostin levels between both the treatment groups 
showed a significant increase in LLLT group than RSD at the 3rd month (P < 0.05). Conclusion: Within the limitations of the 
present study, LLLT application was found to have additional benefits over RSD with respect to clinical periodontal parameters 
and GCF periostin levels. Moreover, periostin may be used as a possible biomarker to evaluate the outcome following NSPT.
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and periodontal disease like phenotype.[5] Its 
expression is downregulated in human periodontal 
ligament fibroblasts when exposed to tumor 
necrosis factor‑alpha (TNF‑α) and Porphyromonas 
gingivalis (P.g) lipopolysaccharide both of which are 
present abundantly in periodontitis.[7]
Removal of bacterial deposits and their toxins from the 
root surface and within the periodontal pockets is not 
completely achieved with conventional mechanical 
nonsurgical debridement alone. Hence, adjunctive 
therapies like low‑level laser therapy (LLLT) have 
been developed.
LLLT biostimulation causes fibroblast proliferation, 
maturation and stimulates the production of basic 
fibroblast growth factor (bFGF), reduces plaque levels, 
gingival inflammation, enhances wound healing, and 
increases bone deposition.[8‑10]
The use of noninvasive biomarker diagnostic 
techniques can help us further understand if any 
improvement does occur at the molecular level to 
further support the use of adjuvant laser therapy. 
To the authors’ knowledge, there is no clinical study 
to evaluate the changes in periostin levels following 
LLLT as an adjunct to root surface debridement (RSD).
The aim of the present case–control clinical study 
was to evaluate the periostin levels in chronic 
periodontitis (CP) patients following LLLT as an 
adjunctive to RSD. The hypothesis was that application 
of LLLT along with RSD could improve periostin 
levels in patients with CP.
MATERIALS AND METHODS
Study population
The study protocol was approved by the institutional 
review board of SRM Dental College (SRMU/
MandHS/SRMDC/2013/M.D.S‑PG Student/508). 
Ninety participants of Indian origin were recruited 
for this prospective, case–control clinical study. 
Thirty patients were allocated to systemically and 
periodontally healthy group (Group I) and sixty 
patients were allotted to the CP group (Group II and III).
Patients with generalized CP with a probing depth of 
≥4 mm, with at least 24 teeth remaining were included 
in the study. Patients with a history of systemic 
diseases, smoking, intake of systemic antibiotics in the 
previous 3 months, and history of periodontal surgery 
in the last 6 months were excluded from the study.
Study design
The study period was between December 2013 and 
August 2015. All patients were subjected to full‑mouth 
periodontal examination and radiographic evaluation. 
CP patients recruited were randomly assigned to either 
of the two treatment groups ‑ RSD group (Group II) 
or RSD with LLLT group (Group III) by a coin toss 
method. A single examiner completely blinded to the 
study recorded the baseline clinical parameters, and 
gingival crevicular fluid (GCF) samples were collected 
after 24 h (AB). After sample collection, complete oral 
prophylaxis, full‑mouth RSD within 24 h was done for 
patients in Group II and III. LLLT was done after a week 
following RSD for patients in Group III once a week for 
6 consecutive weeks. A single operator (DK) blinded to 
the baseline parameters performed RSD and LLLT in 
the same controlled environment. All measures were 
taken to eliminate bias in the study design.
Following RSD analgesics were prescribed, however 
patients were instructed to take the medicine only 
if required. The clinical parameters and GCF were 
collected at the 3rd month in Group II and III. During 
the study period, the participants were instructed to 
brush twice a day.
Application of low‑level laser therapy
A diode laser (AMD Picasso, 810 nm diode laser, 
Indianapolis, USA) with the power of 0.7 watts in 
continuous mode was applied over the gingival 
margin with the tip (0.5 mm) pointed into the sulcus. 
The laser was applied at about 0.5–1 mm away from 
the gingival margin for 20 s over each surface covering 
the entire oral cavity.
Clinical evaluation
Probing pocket depth (PPD), clinical attachment 
level (CAL), and sulcular bleeding index (SBI) were 
assessed at the baseline for all the three groups, and 
after 3 months in Group II and III.
Gingival crevicular fluid sample collection
GCF samples were collected with a microcapillary 
pipette (Hirschmann, Sigma‑Aldrich, USA) from 
all the ninety study patients (Group I, II, and III) at 
the baseline and at the 3rd month in Group II and III 
following nonsurgical treatment from the deepest 
probing site. The collected GCF was stored at −80°C 
until analyzed for periostin using Enzyme Linked 
Immunosorbent Assay (Aviscera Biosciences, Santa 
Clara, California, USA). The sensitivity of the kit 
was 5 ng/mL. Intra‑assay precision was 4–6% and 
inter‑assay precision was 8–12%.
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Statistical analysis
Statistical analysis was performed using the IBM 
SPSS Statistics for windows, Version 22.0, (IBM 
Corp., Armonk, NY). Quantitative data were 
recorded as a mean ± standard deviation. One‑way 
ANOVA followed by “Tukey’s (honest significant 
difference [HSD])” post hoc was performed to check for 
significance between the three groups at the baseline. 
Independent sample t‑test was performed to check 
for significance between mean values of Group II 
and III at the 3rd month. Paired t‑test was done to 
compare the mean values between Group II and III at 
different time points. Periostin levels at the baseline 
and after 3 months were correlated with all the clinical 
parameters in both Group II and III using Pearson’s 
correlation.
RESULTS
The patient’s characteristics such as age, “mean PPD, 
CAL, and SBI” and periostin levels are represented 
in Table 1.
Assessment of periostin level in gingival crevicular 
fluid
Group II and III periostin levels were lesser than 
Group I at the baseline. Following nonsurgical 
periodontal treatment (NSPT), the periostin values 
increased in both Group II and III. The mean periostin 
level in Group III was higher when compared to 
Group II at 3rd month [Table 1].
Comparison of baseline periostin levels between the 
three groups showed statistically significant difference 
between the groups (P < 0.001). “Tukey’s HSD” 
post hoc showed that periostin levels were significantly 
higher in Group I when compared to Group II and III 
(P < 0.001, statistics not represented in table).
Comparison of periostin levels between baseline 
and 3rd month in Group II and III was statistically 
significant (P < 0.05). Comparison of periostin levels 
between Group II and III at 3rd month was found to 
be statistically significant (P < 0.001) [Table 2].
Assessment of clinical parameters and periostin at 
the 3rd month
Comparison of mean PPD, CAL, and SBI at baseline 
and 3 months following NSPT in Group II and III 
showed statistically significant difference (P < 0.001) 
[Table 3]. Similarly, intergroup comparison of clinical 
parameters at the 3rd month between Group II and III 
showed statistically significant difference (P < 0.001) 
[Table 4].
There was a significant correlation between periostin and 
PPD at the baseline in Group II. No correlation was found 
at both baseline and after 3 months between periostin 
and the clinical parameters in Group III [Table 5].
DISCUSSION
In this study, LLLT was used as an adjunct to RSD to 
observe the changes in the levels of periostin. To our 
knowledge, this is the first study in which periostin 
Table 1: Mean and standard deviation values of 
age, sex; clinical parameters and periostin levels at 
baseline and after 3 months
Group I Group II Group III
Number of participants 30 30 30
Male 15 18 17
Female 15 12 13




Table 2: Comparison of mean periostin (ng/ml) at 
baseline and 3 months
Group I Group II Group III
Mean periostin level 
at baseline (ng/ml)
6.54±1.82 3.46±1.31 3.57±1.02
ANOVA compare mean 





Baseline 6.54±1.82 3.46±1.31 3.57±1.02
3 months - 4.49±2.10 5.79±1.89
Paired t‑test to compare mean 
periostin level within groups 





Independent t‑test to compare 
mean periostin level between 
Group II and III at 3rd month
- t=2.51
P=0.1
Table 3: Intragroup comparison of clinical parameters 
at baseline and at 3rd month
Group I Group II Group III
Mean PPD at baseline (mm) 2.25±0.20 4.59±0.46 3.55±0.30
Mean PPD at 3 months - 3.54±0.78 2.29±0.63
Intragroup comparison of 





Mean CAL at baseline 0.0 3.81±0.71 2.65±0.34
Mean CAL at 3 months - 2.44±0.51 1.75±0.52
Intragroup comparison of 





Mean SBI at baseline 0.26±0.05 2.38±0.48 2.57±0.81
Mean SBI at 3 months - 0.8120±0.11 0.4863±0.43
Intragroup comparison of 





PPD: Probing pocket depth, CAL: Clinical attachment level, SBI: Sulcular bleeding 
index
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has been used to evaluate the outcome of nonsurgical 
periodontal therapy using LLLT as an adjuvant to RSD.
At the 3rd month, periostin level was increased when 
compared to the baseline in both Group II and III. 
Moreover, there was a greater increase in GCF 
periostin and improvement in clinical parameters in 
Group III than Group II at the 3rd month (P < 0.05).
The outcome of periodontal therapy is conventionally 
based on an assessment of clinical parameters. Laser 
biostimulation brings about a marginal improvement 
of such clinical parameters.[9,10] To understand the 
dynamics at the molecular level, periostin was 
estimated along with the clinical parameters.
Connective tissue homeostasis is maintained by 
signaling molecules in extracellular matrices.[11] 
Identification of changes in these molecules can help 
us to detect the presence of active disease, predict 
future disease progression, and evaluate the response 
to periodontal therapy. Periostin regulates collagen 
fibrillogenesis, wound repair, angiogenesis, improves 
cell survival and is downregulated in periodontal 
disease.[3,4,12] Similar effects are seen with LLLT 
biostimulation as well. Qadri et al., Yu et al., and 
Almeida‑Lopez et al. in their studies have shown 
that LLLT induces fibroblast proliferation, and the 
stimulated fibroblasts are organized in parallel 
bundles.[9,13,14] In addition, LLLT promotes collagen 
synthesis, angiogenesis, and release of growth factors 
thereby accelerating wound healing.[8‑10] Hence, 
periostin was chosen to evaluate the adjuvant effects 
of LLLT in this study. Furthermore, to identify 
site‑specific changes, GCF was assessed.
Periostin levels significantly reduced in CP patients 
when compared to healthy individuals (P < 0.001). This 
is in agreement with the studies by Padial‑Molina et al., 
Aral et al., Balli et al.[15‑17] Aral et al. found a significant 
decrease in GCF periostin levels in aggressive and 
CP patients when compared to nonperiodontitis 
patients.[16] In a similar study, Balli et al. analyzed 
GCF and serum periostin levels in healthy, gingivitis 
and CP patients and concluded that GCF periostin 
concentration decreased with the periodontal disease 
severity.[17]
Periostin levels were significantly higher at the 
3rd month when compared to the baseline values in 
both the Groups (II, III) (P < 0.05). CP is initiated by 
complex microbes in plaque biofilm. The red complex 
organisms comprising of P.g, Treponema denticola, 
and Tannerella forsythia are considered periodontal 
pathogens and are expressed at the sites of progressing 
periodontitis.[18] An In vitro study by Padial‑Molina 
et al. showed decreased expression of periostin in 
periodontal ligament fibroblast when exposed to P.g 
and TNF‑α.[7] Long‑term studies have shown that 
there is a reduction in the levels of bacteria such as 
Aggregatibacter actinomycetamcomitans, Prevotella 
intermedia, P.g, and proinflammatory cytokines 
following LLLT application.[10,19] The increase in 
periostin levels in Group II and III from the baseline 
was perhaps due to the effects of LLLT causing a 
reduction in P.g and TNF‑α both of which decrease 
the expression of periostin. However, lack of microbial 
profile in the present study is a possible limitation.
LLLT with RSD produced a greater increase in periostin 
levels and improvement in clinical parameters when 
compared to RSD alone. This agrees with Qadri 
Table 4: Intergroup comparison of clinical parameters 
and periostin levels
Variable Group Mean t P
PPD Group II 3.54±0.78 6.836 <0.001
Group III 2.29±0.63
CAL Group II 2.44±0.51 5.167 <0.001
Group III 1.75±0.52
SBI Group II 0.81±0.11 4.001 <0.001
Group III 0.48±0.43
Periostin Group II 4.49±2.10 2.510 0.015
Group III 5.79±1.89
PPD: Probing pocket depth, CAL: Clinical attachment 
level, SBI: Sulcular bleeding index
Table 5: Correlation of periostin levels with clinical 

























PPD: Probing pocket depth, CAL: Clinical attachment level, SBI: Sulcular bleeding 
index
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et al. and Padial‑Molina et al.[9,15] Qadri et al. in their 
controlled clinical trial evaluated the effects of LLLT 
as an adjunct to RSD and concluded that significant 
improvement in clinical parameters and GCF MMP‑8 
levels were seen following adjuvant biostimulation.[9] 
An increase in periostin levels was also seen following 
open flap debridement in CP patients by Padial‑Molina 
et al.[15] The improvement in periostin levels seen in 
this study may be attributed to increased motility 
of gingival and periodontal ligament fibroblasts, 
stimulation of cellular adenosine triphosphate, wound 
healing promotion, angiogenesis, and production of 
bFGF and TGF‑β expression by LLLT.[8‑10,20]
However, conflicting outcomes were reported by 
Schwarz et al. and Sgolastra et al.[21,22] Schwarz et al. 
in their systematic review suggest that there is only a 
marginal increase in clinical parameters following LLLT 
as an adjunct to mechanical debridement.[21] Further, 
Sgolastra et al. in their meta‑analysis concluded that 
LLLT as an adjunct to RSD using diode laser showed 
no significant improvement in clinical parameters.[22]
There was a negative correlation seen between periostin 
level and baseline PPD in Group II. This concurs with 
the findings of Aral et al. and Balli et al. wherein they 
found a negative correlation between GCF periostin 
and clinical parameters in CP patients (P < 0.05).[16,17] 
The results of our study show that periostin levels are 
reduced in diseased sites indicating its protective role 
in the homeostasis of periodontium, and there is an 
improvement in its level following NSPT.
CONCLUSION
Periostin holds promise as a reliable inflammatory 
biomarker for diagnosis and to evaluate the outcome 
following therapeutic interventions. Moreover, 
additional treatment with LLLT improves clinical 
parameters and increases periostin levels in CP 
patients.
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